These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 32235782)

  • 1. Perspectives on the Potential Benefits of Antihypertensive Peptides towards Metabolic Syndrome.
    Jahandideh F; Wu J
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32235782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?
    Karagiannis A; Mikhailidis DP; Athyros VG; Kakafika AI; Tziomalos K; Liberopoulos EN; Florentin M; Elisaf M
    Expert Opin Ther Targets; 2007 Feb; 11(2):191-205. PubMed ID: 17227234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome.
    Putnam K; Shoemaker R; Yiannikouris F; Cassis LA
    Am J Physiol Heart Circ Physiol; 2012 Mar; 302(6):H1219-30. PubMed ID: 22227126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Methoxyestradiol ameliorates metabolic syndrome-induced hypertension and catechol-O-methyltransferase inhibited expression and activity in rats.
    Azhar AS; Zaher ZF; Ashour OM; Abdel-Naim AB
    Eur J Pharmacol; 2020 Sep; 882():173278. PubMed ID: 32544503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid receptor antagonists and the metabolic syndrome.
    Tirosh A; Garg R; Adler GK
    Curr Hypertens Rep; 2010 Aug; 12(4):252-7. PubMed ID: 20563672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity.
    Frigolet ME; Torres N; Tovar AR
    J Nutr Biochem; 2013 Dec; 24(12):2003-15. PubMed ID: 24120291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome.
    Sharma AM; Engeli S
    J Cardiometab Syndr; 2006; 1(1):29-35. PubMed ID: 17675902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension in Metabolic Syndrome: Novel Insights.
    Katsimardou A; Imprialos K; Stavropoulos K; Sachinidis A; Doumas M; Athyros V
    Curr Hypertens Rev; 2020; 16(1):12-18. PubMed ID: 30987573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Renin-Angiotensin system inhibition on cardiovascular events in older hypertensive patients with metabolic syndrome.
    Zreikat HH; Harpe SE; Slattum PW; Mays DP; Essah PA; Cheang KI
    Metabolism; 2014 Mar; 63(3):392-9. PubMed ID: 24393433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catestatin peptide of chromogranin A as a potential new target for several risk factors management in the course of metabolic syndrome.
    Bourebaba Y; Mularczyk M; Marycz K; Bourebaba L
    Biomed Pharmacother; 2021 Feb; 134():111113. PubMed ID: 33341043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of renin: an updated review of the development of renin inhibitors.
    Li YC
    Curr Opin Investig Drugs; 2007 Sep; 8(9):750-7. PubMed ID: 17729187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the brain renin-angiotensin system in hypertension: implications for new treatment.
    Marc Y; Llorens-Cortes C
    Prog Neurobiol; 2011 Oct; 95(2):89-103. PubMed ID: 21763394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart Rate Variability in Patients with Hypertension: the Effect of Metabolic Syndrome and Antihypertensive Treatment.
    Maciorowska M; Krzesiński P; Wierzbowski R; Gielerak G
    Cardiovasc Ther; 2020; 2020():8563135. PubMed ID: 33123219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-angiotensin system blockers affect cognitive decline and serum adipocytokines in Alzheimer's disease.
    Furiya Y; Ryo M; Kawahara M; Kiriyama T; Morikawa M; Ueno S
    Alzheimers Dement; 2013 Sep; 9(5):512-8. PubMed ID: 23142434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin receptor and tumor necrosis factor-α activation contributes to glucose intolerance independent of systolic blood pressure in obese rats.
    Rodriguez R; Lee A; Mathis KW; Broome HJ; Thorwald M; Martinez B; Nakano D; Nishiyama A; Ryan MJ; Ortiz RM
    Am J Physiol Renal Physiol; 2018 Oct; 315(4):F1081-F1090. PubMed ID: 29993275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STRUCTURAL CHARACTERISTICS AND ANTIHYPERTENSIVE EFFECTS OF ANGIOTENSIN-I-CONVERTING ENZYME INHIBITORY PEPTIDES IN THE RENIN-ANGIOTENSIN AND KALLIKREIN KININ SYSTEMS.
    Manoharan S; Shuib AS; Abdullah N
    Afr J Tradit Complement Altern Med; 2017; 14(2):383-406. PubMed ID: 28573254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy in metabolic syndrome: breaking the wheel by targeting the renin-angiotensin system.
    Menikdiwela KR; Ramalingam L; Rasha F; Wang S; Dufour JM; Kalupahana NS; Sunahara KKS; Martins JO; Moustaid-Moussa N
    Cell Death Dis; 2020 Feb; 11(2):87. PubMed ID: 32015340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioactive peptides: are there more antihypertensive mechanisms beyond ACE inhibition?
    Marques C; Amorim MM; Pereira JO; Pintado ME; Moura D; Calhau C; Pinheiro H
    Curr Pharm Des; 2012; 18(30):4706-13. PubMed ID: 22725850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of the pancreatic renin-angiotensin system in insulin resistance and the metabolic syndrome.
    Leung PS; de Gasparo M
    J Cardiometab Syndr; 2006; 1(3):197-203. PubMed ID: 17679833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.